MedTrace Logo

Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis

NCT01245140 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-12-21

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to demonstrate the improvement in the skin condition rate of patients receiving alitretinoin compared to patients receiving placebo.

Conditions

Interventions

DRUG

alitretinoin

to receive verum (20 patients)

DRUG

Placebo

to receive placebo (10 patients)

Sponsors & Collaborators

  • Basilea Pharmaceutica

    collaborator INDUSTRY

  • Stiefel, a GSK Company

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-26
Primary Completion
2014-03-12
Completion
2014-04-16

Countries

  • France
  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245140 on ClinicalTrials.gov